Botulinum TOX TYP a 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTDX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,746
Award facts
- Contract value 100% obligated
- $12,746.43 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,746.43 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botulinum Toxin Type A 1S. The contract, awarded on December 3, 2025, carries a firm fixed-price structure with an ultimate completion date of December 11, 2025, and was issued without a set-aside designation. This delivery order was executed under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional pharmaceutical suppliers for Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through its role as a prime vendor under the PPV-G GEN V framework, which authorizes the DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support recurring medical supply needs across military healthcare operations globally. The company's single-award IDC, established on November 13, 2025, carries a $499,999,999 ceiling value with a completion date of December 31, 2036, and encompasses a 30-month base period with three optional 30-month renewal periods. The current delivery order reflects DMS Pharmaceutical Group's established performance capability across diverse and specialized pharmaceutical requirements, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FBTDX?
SPE2DR26FBTDX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FBTDX worth?
The government has obligated $12,746 on SPE2DR26FBTDX.
Is contract SPE2DR26FBTDX an order under another contract?
Yes. SPE2DR26FBTDX is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTDX competed?
The extent of competition for SPE2DR26FBTDX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award